Dian Diagnostics Group (300244) Fundamentals 2026 — P/E 79.4x, Revenue Analysis | SniperIQ
Dian Diagnostics Group (300244) is a CN-listed Healthcare company in Medical - Diagnostics & Research with a market capitalization of ¥10.7B, trading at ¥17.20 on the SHZ. This SniperIQ fundamentals page covers Dian Diagnostics Group's valuation (P/E 79.4x, P/B 1.6x), profitability (net margin 1.3%), revenue (¥10.1B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Dian Diagnostics Group's market cap?
Dian Diagnostics Group (300244) has a market capitalization of approximately ¥10.7B, trading at ¥17.20 on the SHZ. Market cap moves with the live share price.
What is Dian Diagnostics Group's P/E ratio?
Dian Diagnostics Group's trailing twelve-month P/E ratio is 79.4x, with a price-to-book (P/B) of 1.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Dian Diagnostics Group?
Dian Diagnostics Group runs a net profit margin of 1.3%, a gross margin of 29.2%, and an operating margin of 4.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Dian Diagnostics Group generate?
Dian Diagnostics Group reported revenue of ¥10.1B for fiscal year 2025, with net income of ¥44M and earnings per share (EPS) of 0.0721. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Dian Diagnostics Group pay a dividend?
Dian Diagnostics Group offers a trailing dividend yield of about 2.0%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Dian Diagnostics Group financially healthy?
Dian Diagnostics Group carries a debt-to-equity ratio of 0.38x and a current ratio of 2.73x, with a market beta of 0.69. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Dian Diagnostics Group a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Dian Diagnostics Group (300244) the key facts are: market cap ¥10.7B, P/E 79.4x, revenue ¥10.1B, 52-week range 14.48-33.3. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Dian Diagnostics Group's full fundamentals live
Get Dian Diagnostics Group's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.